Botulinum Toxin Brands in the U.S.

Botulinum toxin brands are product identities, not interchangeable names for one medicine. Each product has its own manufacturer or commercialization path, toxin type, potency assay, label, formulation, and market history.

The U.S. brand map is especially useful because several products are often compared in aesthetic practice even though their units and labels remain product-specific. Shared type A biology does not make Botox, Dysport, Xeomin, Jeuveau, Daxxify, or Letybo unit-equivalent.

Unit caution

Botulinum toxin potency units are specific to each product’s preparation and assay. U.S. labels warn against comparing or converting units across products.

U.S. Aesthetic Type A Brands

Brand	U.S. approval anchor	Manufacturer / commercialization context	Product identity
Botox	1989 therapeutic Botox 🔗; 2002 Botox Cosmetic approval 🔗	AbbVie / Allergan	OnabotulinumtoxinA reference brand with broad therapeutic and aesthetic visibility.
Dysport	2009 U.S. label anchor 🔗	Ipsen product context; Galderma U.S. aesthetic commercialization	AbobotulinumtoxinA product with a long global comparison history.
Xeomin	2010 U.S. label anchor 🔗	Merz Pharma	IncobotulinumtoxinA product often discussed through formulation and handling context.
Jeuveau	2019 U.S. label anchor 🔗	Evolus commercialization; Daewoong Pharmaceutical manufacturing	PrabotulinumtoxinA-xvfs U.S. aesthetic brand connected to Nabota’s Korea-origin product identity.
Daxxify	2022 U.S. label anchor 🔗	Revance / Crown Laboratories	DaxibotulinumtoxinA-lanm product described by Revance as peptide-formulated.
Letybo	2024 FDA approval snapshot 🔗	Hugel	LetibotulinumtoxinA-wlbg U.S. aesthetic brand connected to Hugel’s Korea-origin portfolio.

U.S. Therapeutic Serotype Reference

Brand	U.S. approval anchor	Manufacturer / commercialization context	Product identity
Myobloc / Neurobloc	2000 U.S. approval letter 🔗	Supernus Pharmaceuticals current company context	RimabotulinumtoxinB type B reference for therapeutic interpretation, not an aesthetic type A peer.

International And New Serotype Context

Brand	Current regulatory anchor	Company context	Product identity
Relfydess	Approved in 33 markets and launched in more than 20 as of July 1, 2026; the U.S. BLA received a CRL.	Galderma	RelabotulinumtoxinA, a Galderma-developed type A product with a ready-to-use liquid presentation.
Boey	Canadian approval record in June 2026 and European Commission approval in July 2026; not documented here as FDA approved.	AbbVie / Allergan	TrenibotulinumtoxinE, a type E product distinct from the Botox type A franchise.

How Brand Names Connect

Product names often travel across companies, licensing arrangements, and regions. Jeuveau connects the U.S. aesthetic label to Daewoong’s Nabota manufacturing identity. Letybo connects the U.S. label to Hugel’s broader Botulax / Letybo product family. Myobloc and Neurobloc show how a type B product may carry different regional names, while Boey shows why a separate type E product should not be folded into the type A comparison set. Relfydess separates Galderma’s own product-development role from its licensed Dysport commercialization role.

Those connections are useful for market mapping, but they do not create one global label. A product name used in one country may have different approval language, vial presentations, indications, or distribution partners elsewhere.

Comparison Paths

Readers comparing products should start with product identity before asking about clinical use:

Comparison question	Best starting point
Which companies are behind the brand?	The company directory separates developers, manufacturers, owners, and commercialization partners.
Is it type A or type B?	Type A vs type B explains serotype differences without implying substitutability.
Can units be converted?	Botulinum toxin and product labels explain why unit systems are product-specific.
Is a use approved?	Current prescribing information and regulator records define approval in a specific market; the U.S. FDA indication matrix summarizes current U.S. labeled indications, the U.S. FDA approval timeline collects major FDA anchors for current U.S.-visible brands, and Japan approval context explains how to read Japanese product-information and PMDA-based approval claims.

Sources

The brand entries rely mainly on prescribing information, regulator records, and official company or commercialization materials. Market visibility, online product pages, and familiar clinical use are not treated as proof of approval or superiority.